AKORN, INC.

QUALITY COMPLIANCE COMMITTEE CHARTER

A. Status

The Quality Compliance Committee (the "Committee") is a committee of the Board of Directors (the "Board") of Akorn, Inc. ("Akorn" or the "Company").

B. Purpose

The purpose of the Committee is to assist the Board with oversight of Akorn's compliance with the U.S. federal Food, Drug and Cosmetics Act, as amended, including requirements issued by the U.S. Food and Drug Administration ("FDA") and comparable applicable laws and regulations related to product safety and quality, as well as Akorn's quality compliance practices. The Committee will fulfill this responsibility by carrying out the activities enumerated in Section D of this Charter.

C. Membership

The Committee shall consist of three or more directors as determined by the Board. Each member of the Committee shall be a non-employee director of Akorn and shall be free of any relationship that, in the opinion of the Board, would interfere with the member's individual exercise of his or her judgment. All members of the Committee shall have a general understanding of current good manufacturing practices and applicable compliance and quality standards in the pharmaceutical industry. Such understanding may be obtained through formal education and training or prior relevant work experience within the pharmaceutical industry. Committee members may enhance their understanding and knowledge of the areas the Committee oversees by attending relevant educational programs.

Unless the Board elects a Chair of the Committee, the Committee shall elect a Chair by majority vote. The Chair (or in his or her absence, a member designated by the Chair) shall preside at all meetings of the Committee and set the agenda for each Committee meeting.

Members of the Committee shall be appointed annually by the Board, upon the recommendation of the Nominating and Corporate Governance Committee.

D. Duties and Responsibilities

To fulfill its duties and responsibilities, the Committee shall:

1. Review and oversee Akorn's quality compliance program, including, but not limited to, receiving updates about the activities of Global Quality Compliance ("GQC") and implementation of Akorn's Quality System Corrective Action Plan ("QSCAP"), comparing program components to industry best practices and evaluating to assess whether Akorn's program components raise any significant quality concerns.

2. Oversee and monitor Akorn's quality compliance practices by reviewing and evaluating (based on criteria determined by the Committee) reports and presentations from Akorn's regulatory compliance executives, including the

following:

a. while Akorn is remediating OAI status of its manufacturing facilities, receive and review quarterly written or oral presentations from Akorn senior management that summarize topics such as status of QSCAP remediation and quality initiatives, including management's analysis of the effectiveness checks conducted by GQC and Akorn's general remediation process and evaluate the consistency of these initiatives and with industry best practices;

b. while Akorn is remediating OAI status of its manufacturing facilities, receive and review quarterly written or oral presentations from Akorn senior management that summarize any such interactions with the FDA and other health authorities, including any progress reports or updates;

c. receive and review quarterly written or oral presentations from Akorn senior management regarding Akorn's internal controls, policies, procedures and training programs for ensuring compliance with legal and regulatory requirements related to product safety and quality, including any significant findings with respect to Akorn's compliance and management's response to any such findings, and evaluate their consistency with industry best practices;

d. receive and review written or oral presentations from Akorn senior management summarizing all FDA Form 483s and warning letters, Akorn's responses to such letters and the steps taken to implement the responses;

e. receive and review written or oral presentations from the Company's senior management regarding the status and/or outcome of any complaints or confidential submissions regarding potential instances of non-compliance with product quality and safety requirements that have been submitted to the Committee or reported within Akorn through other means;

f. receive and review written or oral presentations from the Company's senior management regarding any significant disciplinary action being considered or undertaken against any Akorn executive for failing to properly exercise his or her duties and responsibilities with respect to regulatory compliance, including the nature of the conduct that led to the disciplinary action, the disciplinary action and the reason for it, and analyze whether the underlying conduct reflects any regulatory compliance issues; and

g. receive and review written or oral presentations from the Company's senior management and review the status and/or outcome of any relevant government investigations and external or internal audits relating to product quality and safety, and management's analysis of the conduct that led to the investigation or audit, and analyze whether the underlying conduct reflects any regulatory compliance issues.

3. At least quarterly, orally report to the Board on any material or critical items related to matters presented by Akorn management related to Akorn product safety and quality or quality compliance practices.

4. At least annually, review Akorn's organizational structure and qualifications of

Director level and above personnel in the quality compliance organization.

5. At least annually, prepare an overview for inclusion in Akorn's Annual Report on Form 10-K or Proxy Statement on Form DEFI4A regarding Akorn's Quality Compliance Committee and its initiatives.

6. At least annually, review this Charter and recommend any proposed changes to the Board for approval. Any member of the Committee may submit proposed Charter amendments to the Board. By a majority vote, the Board may approve amendments to this Charter.

E. Meetings

The Committee shall meet as often as it determines is necessary to carry out its responsibilities, but not less frequently than quarterly. Additional meetings may be scheduled as needed and may be called by the Chair of the Committee or, if there is no such chair, by two members of the Committee. The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with the provisions of Akorn's Bylaws that are applicable to a committee of the Board.

Except as otherwise provided by statute, a majority of the members shall represent a quorum of the Committee for the transaction of business at any meeting. Formal action to be taken by the Committee shall be by unanimous written consent or by the affirmative vote of at least a majority of the members present (in person or by telephone conference call) at a meeting at which a quorum is present.

The Committee shall maintain written minutes of its meetings. The Committee may, in its discretion, invite other directors of Akorn, members of Akorn's management or any other person, including, without limitation, outside counsel, whose presence the Committee believes to be desirable and appropriate to attend and observe meetings of the Committee. The Committee may exclude from its meetings any person it deems appropriate.

F. Authority

The Committee shall have the authority to conduct or authorize the conduct of further inquiry into matters under its oversight or otherwise reported to it for the purpose of discharging its duties and responsibilities and ensuring the adequacy of Akorn's policies, procedures and programs for fulfilling its obligations under the laws and regulations pertaining to product safety and quality.

The Committee shall have the resources and authority necessary to discharge its duties and responsibilities, including the authority to retain outside counsel or other experts or consultants, as it deems appropriate. Akorn shall provide appropriate funding, as determined by the Committee, for payment of compensation to any advisors engaged by the Committee, including fees of outside legal counsel.

Adopted: November 5, 2019